Abstract
Personalized medicine, the use of therapies that are targeted to the
individual patient, is a reality today, thanks to a growing emphasis on
biomarker research. Biomarkers are anatomic, physiologic, biochemical or
molecular parameters that are associated with the presence and severity of
specific diseases and illnesses. Biomarkers promise a smoother integration of
diagnostics and therapeutics, and most importantly a reduction in time and
cost for Phase I and II clinical trials.
Anyone looking to take advantage of the opportunities the market for biomarker
research offers will find Kalorama' s Biomarkers: A Market Briefing an
essential study of this emerging market. Not only does the report explain the
types of biomarkers and their myriad diagnostic applications, it tracks
current revenue and forecasts revenue for the following diagnostic segments:
- Cancer (Breast, Ovarian, Prostate, Bladder and Cervical)
- EGFR Testing
- Stroke Diagnosis
Recently, interest in biomarkers has soared due to their proven ability to
speed up pharmaceutical R&D efforts. While the FDA has made significant
progress in accelerating premarket product review processes, the number of
applications for new innovative products reaching the FDA has not accelerated.
The productivity of the drug industry is low and is not significantly
improving.
Biomarkers can increase the efficiency and reduce the risks of the drug
development process. New trial designs and clear guidelines for using efficacy
and safety biomarkers in product development will increase the pace and reduce
the cost of developing safe and effective medical products.
Biomarkers have been shown to reduce time and cost for Phase I and II clinical
trials by replacing clinical endpoints. This is expected to produce the most
profitable segment of the market for companies in this industry. Kalorama' s
Biomarkers: A Market Briefing provides detailed information on how this
promising application for biomarkers is already shaping the market, producing
over $200 million in revenue and expected to quintuple in the next four years.
The report details the revenues associated with clinical trials biomarker
application through 2009, including data on geographic regional revenues.
Biomarkers: A Market Briefing discusses the major products currently marketed
in each disease category as well as the important issues and trends that
serious entrants into this market must take notice of. In-depth profiles of
need-to-know companies in this market are provided, including:
- Biophysical Corp.
- Charles River Laboratories Inc.
- Cyclacel Pharmaceuticals Inc.
- DeCODE Genetics
- Diologic Corp.
- Health Discovery Corp.
- Illumina Inc.
- Imgenex Corp.
- Insilicos LLC
- Metabolon Inc.
- Millennium Pharmaceuticals Inc.
- Peakadilly
- PPD Inc.
- Proteome Sciences plc
- Rules-Based Medicine Inc.
- Targeted Molecular Diagnostics LLC
Kalorama' s trusted information-gathering process provides the most accurate
study of the market for biomarkers available today. Information and analysis
presented in this report is based on extensive interviews with senior
management of top companies and in the biomarker arena. While major research
literature and government information is culled, information is corroborated
and key market insights originate from interviews with industry leaders.
Product managers, marketing managers, business development executives,
advertising agency or investment firm executives, and information and research
center librarians are among the individuals who will find this briefing on the
emerging market for biomarkers essential.
View Cart
